drugset / Trial / NCT01633476

CMV Modulation of the Immune System in ANCA-associated Vasculitis

NCT01633476

RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to determine whether Cytomegalovirus (CMV) reactivation in ANCA-associated vasculitis (AAV) patients can be effectively and safely reduced using an antiviral agent (valaciclovir) and whether this in turn improves the function of the immune system thereby also improving the body's ability to fight other infections. The primary hypothesis is that repeated episodes of CMV reactivation in AAV patients drive the expansion and functional impairment of CMV-specific T-cells, with increased susceptibility to infection. Inhibition of CMV replication with valaciclovir will block further stimulation of CMV specific T-cells and increase the functional capacity of the immune system.

Timeline

Start
2013-07
Primary completion
2016-02
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Valaciclovir Unknown 2 g Oral